Cargando…

Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis

BACKGROUND: Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS) and has been examined for use in secondary progressive multiple sclerosis (SPMS). However, no information regarding blood transcriptional changes induced by IFN treatment in SPMS patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurevich, Michael, Miron, Gadi, Falb, Rina Zilkha, Magalashvili, David, Dolev, Mark, Stern, Yael, Achiron, Anat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654830/ https://www.ncbi.nlm.nih.gov/pubmed/26589141 http://dx.doi.org/10.1186/s12883-015-0495-x

Ejemplares similares

Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients
por: Menascu, Shay, et al.
Publicado: (2020)

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study
por: Harari, Gil, et al.
Publicado: (2023)

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents
por: Gurevich, Michael, et al.
Publicado: (2022)

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
por: Gurevich, Michael, et al.
Publicado: (2022)

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
por: Achiron, Anat, et al.
Publicado: (2021)

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021)

Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2012)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
por: Achiron, Anat, et al.
Publicado: (2022)

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Optimizing multiple sclerosis diagnosis: gene expression and genomic association
por: Gurevich, Michael, et al.
Publicado: (2015)

Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a
por: Menascu, Shay, et al.
Publicado: (2021)

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice
por: Zilkha-Falb, Rina, et al.
Publicado: (2020)

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
por: Achiron, Anat, et al.
Publicado: (2023)

Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine-related Pathways
por: Achiron, A., et al.
Publicado: (2004)

Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
por: Achiron, Anat, et al.
Publicado: (2013)

Unique features of central neuropathic pain in multiple sclerosis: Results of a cluster analysis
por: Rivel, Michal, et al.
Publicado: (2022)

Cognitive function in multiple sclerosis: A long-term look on the bright side
por: Harel, Yermi, et al.
Publicado: (2019)

The Design, Development, and Testing of a Virtual Reality Device for Upper Limb Training in People With Multiple Sclerosis: Single-Center Feasibility Study
por: Kalron, Alon, et al.
Publicado: (2022)

A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort
por: Kalron, Alon, et al.
Publicado: (2015)

Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells
por: Gurevich, Michael, et al.
Publicado: (2009)

Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey
por: Kalron, Alon, et al.
Publicado: (2021)

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis
por: Menascu, Shay, et al.
Publicado: (2023)

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
por: Achiron, Anat, et al.
Publicado: (2021)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Post-CNS-inflammation expression of CXCL12 promotes the endogenous myelin/neuronal repair capacity following spontaneous recovery from multiple sclerosis-like disease
por: Zilkha-Falb, Rina, et al.
Publicado: (2016)

Can Blood Gene Expression Predict Which Patients with Multiple Sclerosis Will Respond to Interferon?
por: Kaminski, Naftali, et al.
Publicado: (2005)

Static Posturography and Falls According to Pyramidal, Sensory and Cerebellar Functional Systems in People with Multiple Sclerosis
por: Kalron, Alon, et al.
Publicado: (2016)

Longitudinal relationships between disability and gait characteristics in people with MS
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis
por: Levi, Izhak, et al.
Publicado: (2021)

The Median Eminence, A New Oligodendrogenic Niche in the Adult Mouse Brain
por: Zilkha-Falb, Rina, et al.
Publicado: (2020)

‘Multi-Epitope-Targeted’ Immune-Specific Therapy for a Multiple Sclerosis-Like Disease via Engineered Multi-Epitope Protein Is Superior to Peptides
por: Kaushansky, Nathali, et al.
Publicado: (2011)

Motoric cognitive risk syndrome in people with multiple sclerosis: prevalence and correlations with disease-related factors
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Unique Gene Expression Patterns in Human T-cell Lines Generated from Multiple Sclerosis Patients by Stimulation with a Synthetic MOG Peptide
por: Mandel, Mathilda, et al.
Publicado: (2005)

Cerebellar volume as imaging outcome in progressive multiple sclerosis
por: Inglese, Matilde, et al.
Publicado: (2017)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Association Between White Matter Microstructure and Verbal Fluency in Patients With Multiple Sclerosis
por: Blecher, Tal, et al.
Publicado: (2019)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8b2eupbj5evii5nbbbtdfeassk